Alexander Lesokhin, MD, on the Potential of Immunotherapy for Myeloma - Cancer Therapy Advisor

Alexander Lesokhin, MD, on the Potential of Immunotherapy for Myeloma

Chapter 2

PD-1 inhibition is noted as very promising for myeloma, though clinical trials haven’t shown a promising ORR. Why do you think this is?

In this segment, Dr Lesokhin discusses the potential of checkpoint inhibition for multiple myeloma.

Chapter 3

Can anything be done to mitigate the toxicity of PD-1/PD-L1 inhibition in myeloma?

In this segment, Dr Lesokhin discusses the management of toxicity related to PD-1 blockade in myeloma, including the possibility of re-challenge.

Chapter 4

What potential does CAR-T cell therapy have in myeloma?

In this segment, Dr Lesokhin discusses how CAR-T cell therapy may be used in patients with multiple myeloma.